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Abstract: Review on PTPRR, with data on DNA/RNA, on the protein encoded and where the gene is implicated. 
 
Identity 
Other names: EC-PTP, PCPTP1, PTP-SL, PTPBR7, 
PTPRQ 
HGNC (Hugo): PTPRR 
Location: 12q15 
DNA/RNA 
Description 
Like its mouse ortholog (Chirivi et al., 2004), the 
human gene PTPRR represents a very complex locus as 
revealed by BLAST searches (Altschul et al., 1990) 
using the collection of deposited PTPRR cDNA query 
sequences (schematic diagram of PTPRR DNA/RNA). 
Transcription 
Differentially regulated promoters drive transcription 
from at least four different sites within the 285 
kilobasepair-spanning genomic region and at five 
positions alternative splicing may occur.  
Part of the resulting alternative transcripts make up the 
NCBI-annotated isoforms #1 through #5 in the 
nucleotide database (NM_002849, NM_130846, 
NM_001207015, NM_001207016 and NR_073474, 
respectively).  
Furthermore, one of the alternative exons resides within 
a region that in the reverse transcriptional orientation is 
annotated as a fumarylacetoacetate hydrolase domain-
containing protein 2 (FAHD2) pseudogene. Thus,  
transcripts including this PTPRR exon - i.e. the isoform 
#5 types - carry FAHD2 antisense sequences that may 
have a regulatory impact on transcripts from the 
functional genes FAHD2A and FAHD2B that reside on 
chromosome 2q11. 
Use of the most upstream promoter results in a ~4 
kilobase-long transcript variant, isoform #1, encoding 
what Augustine and co-workers termed the human 
PTPPBSa isoform (Augustine et al., 2000).  
This protein is equivalent to mouse PTPBR7, a 
canonical receptor-type transmembrane PTP. The 
human PTPPBSα transcript is built from sequences 
derived of 14 exons. This build-up was determined 
back in 2001 by Bektas and co-workers (Bektas et al., 
2001) and recently confirmed and extended with 
isoform #2-specific exonic parts (Menigatti et al., 
2009). 
Within the distal region of the very large intron 2, a 
second alternative promoter is residing that leads to the 
human PTPPBSβ isoform (#3), which equals the mouse 
PTP-SL transcript. Although initially this variant was 
not encountered in human cDNA libraries (Augustine 
et al., 2000), the presence of four expressed sequence 
tags and two independent cDNA deposits 
(NM_001207015, AK295951) in public libraries 
underscore the existence of this transcript isoform in 
human tissue. 
Then, within intron 4 - just proximal of exon 5 - a third 
alternative transcriptional start site is present that 
appears as the origin of the PTPPBSγ (#2) and 
PTPPBSδ (#4) variants (Augustine et al., 2000).  
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Schematic depiction of human gene PTPRR (upper panel), derived alternative transcripts (middle panel) and corresponding protein 
isoforms (lower panel). Arrows in the upper panel indicate the four distinct transcriptional start sites within the 285 kBp PTPRR locus on 
chromosome 12q15. Exon numbers according to transcript isoform #1 (acc.nr. NM_002849) are indicated above the corresponding, 
green boxes. Crimson boxes reflect the alternative first exons produced from the three distal promoters. Alternative spliced exonic parts 
are in dark-blue. The sky-blue area within intron 11 reflects the position of a pseudogene in the opposite transcriptional orientation. In the 
middle panel the build-up of the nine different PTPRR transcripts, deduced based on cDNA deposits in public databases, is depicted. The 
respective exon-derived sequence blocks are colour-coded as indicated above and are depicted unfused, to facilitate comparison with 
the gene build-up. See text for more details. The accession numbers for the major database entries defining the transcript variants #6 to 
#9 are given. The first five mRNAs correspond to annotated reference sequences (accession numbers are mentioned in the text). In the 
lower panel, again to facilitate comparison with gene and transcript build-up, the exon-encoded protein contributions are depicted 
unfused. Moreover, flanking the open reading frames (thick boxes) the non-coding mRNA parts are shown as thin white bars. The N-
terminal, salmon protein domain reflects the signal peptide (SP). The transmembrane spanning region (TM) in PTPPBSα and PTPPBSβ 
is shown in turquoise and the kinase-interacting motif (KIM) and protein tyrosine phosphatase catalytic domain (PTP) are coloured purple 
and orange, respectively. The asterisks indicate a conserved furin-like cleavage site and the black dot in the exon 13-derived amino acid 
sequence represents the essential catalytic site cysteine. A dashed pink box indicates the 30 aa open reading frame that is predicted 
based on database entry BX571751. Black arrows point to the position of methionines that may be functional as alternative starts upon 
PTPPBSγ/δ translation. Drawings are to scale (except for exon sizes in the top panel) and size bars are indicated. 
 
Initially, it was thought that perhaps two different 
transcription start sites at close distance were used; an 
upstream one rendering isoform #4 and a second one, 
that would yield isoform #2, just some 200 base pairs 
downstream and within the part that is spliced out in 
transcript #4. However, multiple cDNA reads in the 
public database (most notably BX571751) disclose that 
transcription initiation of isoform #2 type mRNAs in 
fact occurs at the more upstream alternative promoter 
as well. Thus, in- or exclusion of a single sequence 
stretch just proximal of the canonical exon 5 appears 
the discriminating factor between isoforms #2 and #4. 
Mining the non-redundant nucleotide database did not 
provide entries that would back up the PBSγ and PBSδ 
"+/-" additional alternatives that were suggested more 
than a decade ago (Augustine et al., 2000). 
RNA variants represented by isoform #5 (acc. 
NR_073474) and database entry BC072386 also result 
from the use of the PBSγ/δ type promoter. These 
variants are unique, however, due to the splicing out of 
exon 7 and the inclusion of two alternative exons that 
reside in introns 10 and 13, respectively. Since exon 7 
contributes 187 nucleotides, its exclusion alters the 
PTPRR reading frame and results in the incorporation 
of three exon 8-encoded missense amino acids 
followed by a premature stop. Thus, although isoform 
#5 is annotated as a noncoding RNA, truncated proteins 
that span the first 91 or 130 amino acids of PBSγ or 
PTPRR (protein tyrosine phosphatase, receptor type, R) Erkens M, et al. 
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PBSδ, respectively, and then end with KYQ* may 
exist. 
The above-discussed alternative exon within intron 10 
is the one that overlaps with pseudogene FAHD2P1 
that is annotated on the complementary strand. Perhaps 
due to remnants of transcriptional sequence elements 
that relate to the pseudogene, a bit more downstream in 
intron 11 there may be a potential promoter driving 
transcription of the last four PTPRR exons only.  
Evidence for this comes from nucleotide database 
entries AK091647 (#9), AL711271 and most notably 
CR749836 (#8). The resulting transcript, with inclusion 
of a few hundred nucleotides contributing its poly-A 
tail, may well represent the ~3 kilobase-sized mRNA 
that has been detected in Northern blot analyses 
(Augustine et al., 2000). An open reading frame that 
constitutes the C-terminal 87 amino acids of the 
PTPRR PTP domain, hence representing an 
enzymatically inactive N-terminal truncation mutant, is 
discernible. It remains to be investigated whether the 
intron 11 transcription start is indeed genuine and 
whether the resulting RNAs have coding potential. 
The cDNA in entry AK091647 (#9) yields one more 
surprise for the human PTPRR locus; 110 additional 
nucleotides directly upstream of exon 12 are retained 
within this clone. These additional bases were also 
found in AK304672 (#7), demonstrating that an 
alternative splice acceptor site for the exon 12 5' start 
exists.  
Usually, the distal site is used and exon 12 donates 158 
bases to the maturing transcript. In the cases just 
mentioned, the proximal site was used and the 
elongated exon 12 contributes 268 bases. If this occurs 
in transcripts originating from the upstream promoters, 
the PTPRR reading frame will dictate the addition of a 
single lysine to the protein before a stop codon is 
encountered. Hence, the resulting protein will lack the 
121 C-terminal residues of the catalytic domain and 
will be enzymatically inactive. The predicted open 
reading frame within the transcripts dictated by the 
fourth, intron 11-residing promoter, however, is not 
altered by the exon 12 splice acceptor choice since the 
AUG start codon is contributed by the shared exon 12 
part. 
It is of note that directly downstream of PTPRR, in a 
head-to-tail fashion, yet another receptor-type PTP 
gene is located:  
PTPRB. At first sight, the expression pattern in mouse 
brain is distinct from that of PTPRR (Lein et al., 2007; 
Hawrylycz et al., 2012) and future research will have to 
unveil whether both genes share transcriptional 
regulatory elements. 
Pseudogene 
There are no pseudogenes detectable for gene PTPRR 
in the human genome. Its closest relatives are the other 
two genes within the "R7" subclass of  
classical PTPs (Andersen et al., 2001), PTPN5 and 
PTPN7, which encode for STEP and HePTP, 
respectively. 
Protein 
 
PTPRR isoforms nomenclature. * Homology depending on 
the start codon used. 
Description 
From the above it is clear that human PTPRR encodes 
many different PTPRR protein isoforms. The longest 
one is a 657 single-pass transmembrane receptor-type 
PTP by virtue of its N-terminal signal peptide (SP).  
Removal of the SP from the precursor protein will yield 
a 71 kDa mature protein of the PTPBR7 type. This 
human PTPRR isoform #1 may additionally be post-
translationally cleaved at an evolutionary conserved 
furin-like site, in analogy with the mouse ortholog 
(Dilaver et al., 2007), rendering a 59 kDa protein 
spanning 519 residues. This processing site is also 
present in the 545 amino acid long isoform #3 that has 
PTP-SL as its ortholog in mouse.  
It may well be that it is actually the second AUG codon 
that is being used for the start of translation, as it was 
found in mouse (Chirivi et al., 2004). In that case, the 
PTPPBSβ open reading frame would be 30 nucleotides 
shorter, and a 535 residue-spanning protein of 60 kDa 
would be synthesised.  
Although isoform #3 lacks an obvious signal peptide 
preceding the transmembrane segment, one may expect 
that like PTP-SL (Noordman et al., 2008) it will behave 
as a type III transmembrane molecule (Spiess, 1995). 
Human PTPRR transcript type #4 displays an open 
reading frame that predicts the synthesis of a 451 aa 
PTPRR isoform, coined PTPPBSδ (Augustine et al., 
2000), that has a unique three amino acid N-terminus 
before it proceeds with the exon 5-encoded PTPRR 
read.  
Consequently, this predicted 51 kDa protein contains 
the TM segment and may be topologically similar to 
the PTPPBSβ protein isoform #3. The original PTPRR 
transcript #2 was thought to have its coding region 
starting exactly three nucleotides before exon 6-derived 
sequences, hence resulting in a 46 kDa cytosolic 
protein that spans 412 residues and is lacking any 
meaningful hydrophobic part.  
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Ribbon (A) and surface (B) type representation of the three-dimensional structure of the PTP domain in human PTPRR, as determined 
by X-ray crystallograpy (PDB code: 2A8B; (Eswaran et al., 2006)). Numbers are according to PTPPBSα protein isoform #1. Relevant 
structural elements, mentioned in the text, are indicated. The KIM domain and the α0 helix that was observed in the mouse PTPRR 
structure (PDB code: 1JLN) are N-terminal of Ser375 and were absent in the human recombinant protein part used for crystallization. 
Blue parts represent alpha helices and red domains symbolize beta strands. Yellow portions indicate 310 helices and the green parts 
represent ramdom coil segments. Molecular graphics was created with YASARA (Krieger et al., 2002). 
 
Multiple cDNAs now argue in favour of extending the 
5' end of the type #2 transcript and by doing so the 
(more) full-length cDNA then only displays a rather 
short, 30 aa protein-encoding ORF due to a stop codon 
in the part that is spliced out in isoform #4-type 
transcripts. 
Adding to the complexity is that in mouse PTPPBSγ 
mRNA it is not the first but rather the second and third 
AUG codon that is used by the translational machinery 
(Chirivi et al., 2004). If the same holds true in human, 
then the PTPPBSγ/δ-type transcripts would yield 42 
and 37 kDa sized cytosolic PTPs independent of the in- 
or exclusion of the 283 nucleotide intron preceding 
exon 5. 
There are two domains that are present in all PTPRR 
proteins encoded by transcript isoforms #1 through #4; 
a so-called kinase interaction motif (KIM (Pulido et al., 
1998)) and, of course, the catalytic PTP domain. This 
classical, strictly phosphotyrosine-specific catalytic 
PTP segment spans some 280 conserved amino acids 
and includes the active site cysteine that is essential for 
the nucleophile attack on the phosphorus of the 
phosphotyrosine in the substrate protein (Guan and 
Dixon, 1991). Overall, the three-dimensional structure 
of PTP domains shows only minor differences in the 
core elements. For instance, the structure of the 
catalytic segment in the "R7" PTP subfamily (that is 
comprised of PTPRR, STEP and HePTP (Andersen et 
al., 2001)) displays a short β sheet consisting of the N-
terminal βx and C-terminal βγ strands (Eswaran et al., 
2006) that is not encountered in the founding PTP1B 
structure (Barford et al., 1994). Also, this R7-type PTP 
domain structure contains several helices (Szedlacsek 
et al., 2001; Mustelin et al., 2005; Eswaran et al., 2006) 
that are additional to the canonical structure in other 
PTPs (Barr et al., 2009). Most notably, PTPRR, STEP 
and HePTP have an additional N-terminal helix 
(termed "α0") that is stabilized by hydrophobic 
interactions with helix α5 and the loop following helix 
α2' (Szedlacsek et al., 2001; Mustelin et al., 2005; 
Eswaran et al., 2006). This results in a hydrophobic 
cavity of ~16Å depth that may be instrumental in the 
regulation of enzyme activity and substrate specificity 
(Szedlacsek et al., 2001). Helix α0 is located 15 
residues downstream of the KIM motif, a 16 amino 
acid sequence that is essential for PTPRR's interaction 
with the MAP kinases ERK1, ERK2, ERK5 and p38 
(Pulido et al., 1998; Zúñiga et al., 1999; Buschbeck et 
al., 2002; Muñoz et al., 2003). Thus, helix α0 may 
facilitate proper positioning of the KIM to ensue 
interactions with the docking groove in MAP kinases 
(Tárrega et al., 2005). As a consequence not only the 
regulatory tyrosine in the MAP kinase's activation loop 
is dephosphorylated, causing its inactivation (Pulido et 
al., 1998), but additionally the physical interaction 
prevents MAP kinase translocation to the nucleus 
(Blanco-Aparicio et al., 1999; Zúñiga et al., 1999). 
Vice versa, the association of a KIM-containing PTP 
with an active MAP kinase triggers specific 
phosphorylation of a threonine residue within the PTP's 
α0 helix (Pulido et al., 1998; Muñoz et al., 2003). The 
consequence of this phosphorylation event, however, 
remains to be investigated. Quite opposite, the effect of 
protein kinase A (PKA)-mediated phosphorylation of a 
conserved serine residue within the KIM motif is well 
studied since it abolishes the binding and subsequent 
dephosphorylation of MAP kinases by KIM-containing 
PTPs (Blanco-Aparicio et al., 1999; Saxena et al., 
1999; Nika et al., 2004). 
The predicted proteins that may result from translation 
of the PTPRR messenger types #5 through #9 will be 
enzymatically dead. The transcript #5 and #6 derived 
types will lack all PTP domain residues and also the 
KIM segment is far from complete, all due to a reading 
PTPRR (protein tyrosine phosphatase, receptor type, R) Erkens M, et al. 
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frame change that is caused by exon 7 skipping. 
Depending on the AUG choice, a small protein that 
would contain the TM domain might be produced, 
which could theoretically influence the multimerization 
behaviour of the PTPBR7 and PTP-SL type isoforms 
(Noordman et al., 2008). PTPRR splice forms that 
manage to maintain the long version of exon 12 (e.g. 
the #7 type), however, will produce protein variants 
that only lack the C-terminal 121 amino acids. Such 
truncated, KIM-containing proteins would be 
enzymatically inactive but may compete with 
endogenous full-length PTPRR isoforms for binding to 
MAP kinases or other PTPRR-associating 
biomolecules. Any regulatory impact of the 
hypothetical 87 amino acid long protein that 
corresponds to the ORF in transcript versions #8 and #9 
would be purely speculative. 
Expression 
Isoform-specific expression studies on human samples 
are limited to RT-PCR analyses (Augustine et al., 
2000) which in general point to expression patterns that 
are quite similar to mouse (Van Den Maagdenberg et 
al., 1999; Augustine et al., 2000) and rat (Watanabe et 
al., 1998). Human PTPPBSα is expressed exclusively 
in brain and the PTPPBSγ/δ-type transcripts are also 
detectable in various other tissues, most notably uterus 
and intestine (Augustine et al., 2000). PTPPBSβ 
isoform expression was not addressed in that study. 
Given that both in mouse and in rat a developmental 
promoter switch occurs in cerebellar Purkinje cells 
(PCs), favouring PTP-SL-type expression in mature 
PCs, it seems likely that also in human cerebellum the 
promoter within PTPRR intron-2 will drive postnatal 
expression of PTPPBSβ isoforms. The notion that 
PTPPBSγ/δ-type isoforms are detectable outside brain 
is of importance for recent studies that implicate 
PTPRR in carcinogenic processes in cervix and colon 
(Menigatti et al., 2009; Su et al., 2013). 
Localisation 
No detailed studies on the subcellular localization of 
human PTPRR protein isoforms have been performed 
and, again, only inference from mouse and rat data 
(Shiozuka et al., 1995; Ogata et al., 1999; Van Den 
Maagdenberg et al., 1999; Dilaver et al., 2003; 
Noordman et al., 2006; Noordman et al., 2008; 
Hendriks et al., 2009) remains. Based on this, it seems 
reasonable to postulate that isoform #1 will display a 
PTPBR7-like cell surface expression and that isoform 
#3 may reside on the trans-Golgi network and 
multivesicular bodies or sorting endosomes, like mouse 
PTP-SL does. Depending on the translational start site 
choice, the other isoforms produce either PTP-SL-like 
vesicle-associated versions or, more likely, cytosolic 
proteins that resemble murine PTPPBSγ. Intriguingly, 
the mouse transmembrane PTPRR isoforms form 
multimeric complexes and their relative PTP activity is 
significantly lower than that of the cytosolic PTPPBSγ 
type (Noordman et al., 2008). This predicts regulatory 
potential for any biomolecule that would bind to the 
PTPBR7 and/or PTP-SL parts that are N-terminal of 
the transmembrane segment. Identification of receptor-
type PTP ligands is a cumbersome process (Stoker, 
2005; Mohebiany et al., 2013) and although mouse 
PTPBR7 extracellular domain displayed a clear affinity 
for highly myelinated brain regions (Chesini et al., 
2011) the corresponding PTPRR ligands still await 
proper identification. 
Function 
The localization of the two transmembrane mouse 
PTPRR isoforms on anterograde as well as retrograde 
endocytic vesicles (Hendriks et al., 2009) suggests 
either a role in the regulation of vesicle transport or a 
fate as cargo in these compartments. In line with the 
first option, protein interaction and transfection studies 
pointed at a potential functional interaction with β4-
adaptin, an AP-4 complex subunit that participates in 
vesicle sorting (Dilaver et al., 2003). Further studies are 
needed to corroborate this finding and it remains to be 
established whether this holds for human PTPRR as 
well. On the contrary, ample evidence now supports a 
regulatory impact for PTPRR isoforms on MAP kinase 
signaling. After the initial ectopic overexpression 
experiments that disclosed the KIM-dependent and 
PKA-regulated PTPRR-MAP kinase interactions 
(Pulido et al., 1998; Blanco-Aparicio et al., 1999; 
Ogata et al., 1999) it was surprising to find that 
endogenous PTPRR apparently was dispensable for 
proper EGF- and NGF-induced MAP kinase activity in 
rat PC12 cells (Noordman et al., 2008). Findings in 
PTPN7 deficient mice, however, had suggested that 
KIM-containing PTP impact on MAP kinase cascades 
might be very subtle (Gronda et al., 2001). 
Furthermore, pharmacological inhibition (Paul et al., 
2003; Valjent et al., 2005) and mouse knock-out studies 
also proved PTPN5 to be a physiological regulator of 
MAP kinase cascades (Venkitaramani et al., 2009). 
Indeed, also Ptprr knock-out mice displayed MAP 
kinase hyperphosphorylation in relevant tissues 
(Chirivi et al., 2007). 
PTPRR's closest homolog, the PTPN5-encoded protein 
STEP, is additionally capable of dephosphorylating the 
cytosolic tyrosine kinase Fyn, Pyk2, and subunits of 
AMPA and NMDA receptors in neuronal cells, 
implicating KIM-containing PTPs in neuronal 
functions like synaptic transmission (Baum et al., 2010; 
Xu et al., 2012a). There is even evidence that PTPN5 is 
linked to the pathophysiology of diverse 
neuropsychiatric disorders in man, including 
Schizophrenia and Alzheimer's disease (Goebel-Goody 
et al., 2012; Xu et al., 2012b). Although direct evidence 
for an impact of PTPRR on Src-family kinase or 
AMPA and NMDA receptor subunit phosphorylation 
levels has not yet been obtained, it remains an 
interesting possibility in view of the phenotypic 
consequences of PTPRR deficiency in mice (Chirivi et 
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al., 2007) and the proposed links with some human 
(neuro)pathological conditions (below). 
Implicated in 
inv(12)(p13q15) in acute myelogenous 
leukemia 
Note 
An inv(12)(p13q15) translocation detected in an acute 
myelogenous leukemia was found to result in multiple 
fusion transcripts spanning the first three or four exons 
of gene TEL in combination with the final five to eight 
exons of PTPRR (Nakamura et al., 2005). Only a single 
chimeric TEL/PTPRR fusion transcript, however, 
dictates an open reading frame that would be in-frame 
with PTPRR sequences. This fusion transcript joins the 
fourth TEL exon with the ninth of PTPRR and results 
in a protein that lacks the first (exon 8-encoded) thirty-
odd residues of the PTP catalytic domain and thus will 
be enzymatically activity. It therefore seems more 
likely that an altered functionality of the TEL 
transcriptional repressor part in the chimeric protein is 
instrumental in the disease. 
Colorectal and cervical cancers 
Note 
Recent findings, however, more directly support a role 
for PTPRR in cancer etiology. RNA expression studies 
in mice highlighted PTPRR isoform expression in the 
epithelial linings of the intestine (Augustine et al., 
2000). Gene expression profile analyses revealed that 
PTPRR transcription was markedly downregulated in 
colorectal tumors as compared to normal mucosa 
(Sabates-Bellver et al., 2007). The decreased 
expression in precancerous and cancerous colorectal 
tumors resulted from epigenetic changes, both at the 
level of CpG island DNA methylation and histone-tail 
modification, that were also observed in colon cancer 
cell lines and were maintained in metastases (Menigatti 
et al., 2009). The finding was recently confirmed in an 
independent study on colon carcinomas (Laczmanska et 
al., 2013) and can now be extended to cervix cancer on 
the basis of a study that concentrated on the 
consequences of DNA methyltransferases 3B 
(DNMT3B) hyperactivity in invasive cervical cancer 
(Su et al., 2013). It turned out that PTPRR was silenced 
through DNMT3B-mediated methylation. Given the 
impact of the RAS/RAF/MAPK signalling axis in 
cancer cell proliferation, it is not difficult to envision 
that PTPRR down-regulation would aid constitutive 
activation of this key pathway. Furthermore, PTPRR 
re-expression was shown to inhibit the expression of 
the oncogenic human papillomavirus E6/E7 proteins 
(Su et al., 2013), providing yet another advantage for 
HPV-positive cells to downregulate this PTP gene.  
PTPRR is normally not only expressed in the cervix but 
also in endometrial tissue. By comparing mRNA levels  
throughout the menstrual cycle, PTPRR was found to 
be increased some fifty-fold from the proliferative to 
the secretory phase in endometrial tissue (Sherwin et 
al., 2008). Furthermore, PTPRR expression appeared 
an additional four-fold higher in late secretory phase 
tissue of women with endometriosis as compared to 
controls, which suggests that PTPRR may prevent 
normal endometrial differentiation and could represent 
a predisposing factor in the aetiology of endometriosis 
(Sherwin et al., 2008). 
Type 2 diabete 
Note 
The mapping of a novel type 2 diabetes susceptibility 
locus on chromosome location 12q15, back in the 
former century, early on triggered the testing of PTPRR 
as a candidate risk gene. Although the subsequent study 
provided a first snapshot of the gene and also yielded 
multiple polymorphisms, none of the identified 
mutations did segregate with diabetes (Bektas et al., 
2001). Thus PTPRR is excluded as a risk gene at the 
type 2 diabetes locus on chromosome 12q15. 
Psychoneuropathologies 
Note 
In prefrontal cortex and hippocampal areas in brains of 
depressed suicide subjects a significant reduction of 
MAP kinase transcript levels and increased amounts of 
a dual-specificity MAP kinase phosphatase have been 
noted (Dwivedi et al., 2001). Intriguingly, 
transcriptome-wide micro-array expression studies on 
postmortem orbitofrontal cortex tissue from violent 
suicide victims subsequently revealed a 1,5-fold 
upregulation of PTPRR mRNA levels when compared 
to controls (Thalmeier et al., 2008). This suggests a 
picture in which the reduction of MAP kinase signals in 
distinct brain areas - for example due to PTPRR 
aberrancies - may ultimately lead to profound mood 
distortions with eventual violent or deadly 
consequences. Such mood disorders are quite hard to 
study in mouse models and also the subtleties in brain 
expression patterns will severely hamper reductionistic 
studies on the psychopathophysiological relevance of 
these findings.  
Recently, however, an additional correlative finding 
aids in building a case for involvement of PTPRR in 
psychoneuropathologies. It is currently well accepted 
that genetic components are contributing to major 
depressive disorder (MDD), a chronic and rather 
common mental disease. Given that reduced MAP 
kinase activity has been noted in MDD pathogenesis 
(Einat et al., 2003; Chen et al., 2006) and that PTPRR 
proteins inhibit this signaling pathway, it made sense to 
test whether PTPRR perhaps represents an MDD risk 
gene. By monitoring the distribution of 16 single 
nucleotide polymorphisms (SNPs) at the PTPRR locus 
in a Chinese Han population indeed one (rs1513105) 
demonstrated allelic association with an increased risk 
for MDD, but primarily in the female subjects (Shi et 
PTPRR (protein tyrosine phosphatase, receptor type, R) Erkens M, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(1) 29 
al., 2012). Replication in additional cohorts will be the 
next step.  
Like for MDD, the heterogeneous etiology of alcohol 
use disorders (AUD) predicts a complex interplay of 
environmental and heritable factors and the latter may 
include impaired MAP kinase signaling circuits. By 
combining genome wide association studies (GWAS) 
and gene set enrichment analyses (GSEA) on subjects 
characterized for alcohol response level phenotypes, a 
set of 173 genes that appear relevant for the disorder, 
among which PTPRR, could be extracted (Joslyn et al., 
2010). Several had a reported involvement in alcohol 
response and addiction, and a specific enrichment for 
neuronal signaling genes - especially the ones 
impacting on glutamate signaling - was apparent 
(Joslyn et al., 2010). Analogous to STEP (Baum et al., 
2010), PTPRR may modulate AMPA and NMDA 
receptor levels and as such is an appealing genetic 
component for the modulation of alcohol's effects. 
Myopia 
Note 
The most recent addition to the list of disease 
associations for PTPRR is that of nearsightedness, or 
myopia (Hawthorne et al., 2013). For this common 
ocular genetic disease over 20 candidate genomic loci 
have been put forward, including one on chromosome 
12q21-23 that links to high-grade myopia. Subsequent 
genetic association studies using hundreds of SNPs 
within the linkage region yielded several that 
significantly associated with the disease, including 
rs3803036 that represents a Lys>Arg missense 
mutation in PTPRR (Hawthorne et al., 2013). 
Microarray analyses revealed that PTPRR is 
differentially expressed in fetal and adult ocular tissue, 
warranting further studies on its role in myopic 
development. 
To be noted 
Note 
Ptprr knockout mice display mild, ataxia-like, 
locomotive impairment (Chirivi et al., 2007) but the 
gene's location in human does not match with the 
various ataxia loci that have been mapped thus far and 
that still await identification of the underlying gene 
defects (Espinós et al., 2009). 
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